Equillium(EQ) - 2023 Q4 - Annual Results

Exhibit 99.1 Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights $40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2 2024 Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients at American Society of Nephrology (ASN) & American College of Rheumatology (ACR) meetings Ono ...